Patents by Inventor Michael Alex Van Hartskamp
Michael Alex Van Hartskamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230393149Abstract: Disclosed is an in vitro method for assessing the presence of gingivitis in a human subject. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a saliva sample of the subject the concentrations are measured of the proteins Hepatocyte growth factor (HGF) and Interleukin-1? (IL-1?), and at least one of C reactive protein (CRP) and Haemoglobin. Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with the absence of gingivitis or periodontitis. The comparison allows to assessing whether the testing value is indicative of the presence of gingivitis in said subject. Thereby, typically, a testing value reflecting a joint concentration above the joint concentration reflected by the threshold, is indicative of the presence of gingivitis.Type: ApplicationFiled: August 22, 2023Publication date: December 7, 2023Inventors: Gerben KOOIJMAN, Michael Alex VAN HARTSKAMP, Marinus Karel Johannes DE JAGER, Amir Hussein RMAILE, Philip PRESHAW, John J. TAYLOR
-
Patent number: 11769591Abstract: A system and computer program are provided for computer aided diagnosis or monitoring of heart failure patients. The system and computer program obtain patient data representing measurements of a select and limited set of health indicators of a patient. A trained classifier is applied to the patient data to obtain a classification of the occurrence or degree of heart failure for the patient. The limited set of health indicators is specifically selected from a large set of health indicators which are known to be predictive of heart failure on the basis of a clinical study which demonstrated the accuracy of the classification using this select set.Type: GrantFiled: June 28, 2019Date of Patent: September 26, 2023Assignee: Koninklijke Philips N.V.Inventors: Marija Despenic, Michael Alex Van Hartskamp
-
Patent number: 11612028Abstract: The invention provides a light management information system for an outdoor lighting network system, having a plurality of outdoor light units each including at least one sensor type, where each of the light units communicates with at least one other light unit, at least one user input/output device in communication with at one or more of said outdoor light units, a central management system in communication with light units, said central management system sends control commands and/or information to one or more of said outdoor light units, in response to received outdoor light unit status/sensor information from one or more of said outdoor light units or received user information requests from said user input/output device, a resource server in communication with said central management system, wherein the central management system uses the light unit status/sensor information and resources from the resource server to provide information to the user input/output device and/or reconfigure one or more of the lType: GrantFiled: April 30, 2021Date of Patent: March 21, 2023Assignee: SIGNIFY HOLDING B.V.Inventors: Hongxin Chen, Dave Alberto Tavares Cavalcanti, Marcin Gramza, Liang Jia, Qing Li, Daniel J. Piotrowski, Marek Zbigniew Szczerba, Marcin Krzysztof Szczodrak, Qin Zhao, Hongqiang Zhai, Michael Alex Van Hartskamp, Martin Elixmann, Zhong Huang, Fulong Ma, Xianneng Peng, Jianfeng Wang, Yi Qiang Yu, Kiran Srinivas Challapali
-
Publication number: 20210382069Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least two of Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient.Type: ApplicationFiled: April 2, 2019Publication date: December 9, 2021Inventors: Gerben KOOIJMAN, Amir Hussein RMAILE, Carl GLASSE, Marinus Karel Johannes DE JAGER, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT, Philip PRESHAW, John J TAYLOR, Michael Alex VAN HARTSKAMP
-
Publication number: 20210329756Abstract: The invention provides a light management information system for an outdoor lighting network system, having a plurality of outdoor light units each including at least one sensor type, where each of the light units communicates with at least one other light unit, at least one user input/output device in communication with at one or more of said outdoor light units, a central management system in communication with light units, said central management system sends control commands and/or information to one or more of said outdoor light units, in response to received outdoor light unit status/sensor information from one or more of said outdoor light units or received user information requests from said user input/output device, a resource server in communication with said central management system, wherein the central management system uses the light unit status/sensor information and resources from the resource server to provide information to the user input/output device and/or reconfigure one or more of the lType: ApplicationFiled: April 30, 2021Publication date: October 21, 2021Inventors: HONGXIN CHEN, DAVE ALBERTO TAVARES CAVALCANTI, MARCIN GRAMZA, LIANG JIA, QING LI, DANIEL J. PIOTROWSKI, MAREK ZBIGNIEW SZCZERBA, MARCIN KRZYSZTOF SZCZODRAK, QIN ZHAO, HONGQIANG ZHAI, MICHAEL ALEX VAN HARTSKAMP, MARTIN ELIXMANN, ZHONG HUANG, FULONG MA, XIANNENG PENG, JIANFENG WANG, YI QIANG YU, KIRAN SRINIVAS CHALLAPALI
-
Patent number: 11075772Abstract: The present invention provides a support system for supporting the commissioning of a networked power distribution system (1). The networked power distribution system comprises at least one power supply (2) with one or more power connectors (12, 12a) for supplying power to the one or more power connectors and a data communication interface for exchanging communication data. The support system (6) comprises one or more load device detectors (7) for detecting the connecting and/or disconnecting of a load device (3a) to/from a power connector (12a), and a commissioning tool (8) for performing steps of commissioning the networked power distribution system with regard to the load device. The commissioning tool is adapted to automatically perform at least some of the commissioning steps in response to the detection of the connecting and/or disconnecting of the load device. This can allow for a relatively easy commissioning of the networked power distribution system.Type: GrantFiled: June 23, 2016Date of Patent: July 27, 2021Assignee: SIGNIFY HOLDING B.V.Inventors: Bozena Erdmann, Matthias Wendt, Michael Alex Van Hartskamp, Willem Franke Pasveer
-
Publication number: 20210181209Abstract: Disclosed is a system, a kit, a use and an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The system and method are based on the insight to apply a clustering technique to a reference set of patient data, and then further discriminating the sets of bio markers to be applied. The clusters are determined on the basis of the biomarkers Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), and Matrix metalloproteinase 9 (MMP9). The actual classification of the patient is done on the basis of the measurement of the concentrations of either of two sets of biomarkers. For one cluster these are Interleukin-1? (IL1?), Interleukin-6 (IL6), and Collagen Telopeptide. For the other cluster, these are HGF and metallopeptidase inhibitor 1 (TIMP1).Type: ApplicationFiled: October 18, 2018Publication date: June 17, 2021Inventors: Supriyo CHATTERJEA, Marinus Karel Johannes DE JAGER, Amir Hussein RMAILE, Gerben KOOIJMAN, Michael Alex VAN HARTSKAMP, Philip PRESHAW, John J TAYLOR
-
Publication number: 20210164995Abstract: Disclosed is an in vitro method for assessing whether a human patient has gingivitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from gingivitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and S100 calcium-binding protein A8 (S100A8), and at least one of Hemoglobin subunit beta (Hb-beta), Keratin 4 (K-4) and Pyruvate Kinase (PK). Another combination is Alpha-1-acid glycoprotein (A1AGP), Hemoglobin subunit beta (Hb-beta) and Keratin 4 (K-4). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with gingivitis. The comparison allows assessing whether the testing value is indicative of the presence of gingivitis in said patient.Type: ApplicationFiled: April 10, 2019Publication date: June 3, 2021Inventors: Gerben KOOIJMAN, Amir Hussein RMAILE, Carl GLASSE, Marinus Karel Johannes DE JAGER, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT, Philip PRESHAW, John TAYLOR, Michael Alex VAN HARTSKAMP
-
Publication number: 20210164996Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Profilin and S100 calcium-binding protein A9 (S100A9). Another combination is Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient.Type: ApplicationFiled: April 12, 2019Publication date: June 3, 2021Inventors: Gerben KOOIJMAN, Amir Hussein RMAILE, Carl GLASSE, Marinus Karel Johannes DE JAGER, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT, Philip PRESHAW, John J TAYLOR, Michael Alex VAN HARTSKAMP
-
Publication number: 20210164994Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Interleukin-1-beta (I-1?) and 5 Matrix metalloproteinase-8 (MMP-8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of 10 periodontitis.Type: ApplicationFiled: April 2, 2019Publication date: June 3, 2021Inventors: Gerben KOOIJMAN, Michael Alex VAN HARTSKAMP, Amir Hussein RMAILE, Carl GLASSE, Philip PRESHAW, John TAYLOR, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT, Marinus Karel Johannes DE JAGER
-
Patent number: 11026317Abstract: The invention provides a light management information system for an outdoor lighting network system, having a plurality of outdoor light units each including at least one sensor type, where each of the light units communicates with at least one other light unit, at least one user input/output device in communication with at one or more of said outdoor light units, a central management system in communication with light units, said central management system sends control commands and/or information to one or more of said outdoor light units, in response to received outdoor light unit status/sensor information from one or more of said outdoor light units or received user information requests from said user input/output device, a resource server in communication with said central management system, wherein the central management system uses the light unit status/sensor information and resources from the resource server to provide information to the user input/output device and/or reconfigure one or more of the lType: GrantFiled: October 22, 2019Date of Patent: June 1, 2021Assignee: SIGNIFY HOLDING B.V.Inventors: Hongxin Chen, Dave Alberto Tavares Cavalcanti, Marcin Gramza, Liang Jia, Qing Li, Daniel J. Piotrowski, Marek Zbigniew Szczerba, Marcin Krzysztof Szczodrak, Qin Zhao, Hongqiang Zhai, Michael Alex Van Hartskamp, Martin Elixmann, Zhong Huang, Fulong Ma, Xianneng Peng, Jianfeng Wang, Yi Qiang Yu, Kiran Srinivas Challapali
-
Publication number: 20210148935Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis.Type: ApplicationFiled: April 10, 2019Publication date: May 20, 2021Inventors: GERBEN KOOIJMAN, AMIR HUSSEIN RMAILE, CARL GLASSE, MARINUS KAREL JOHANNES DE JAGER, IAIN LESLIE CAMPBELL CHAPPLE, MELISSA MACKAY GRANT, PHILIP PRESHAW, JOHN TAYLOR, MICHAEL ALEX VAN HARTSKAMP
-
Publication number: 20210132083Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Hemoglobin subunit delta (Hb-delta) and Pyruvate kinase (PK). Another such combination is Keratin-4 (K-4) and at least two of Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and Matrix metalloproteinase-8 (MMP-8). A third combination is Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis.Type: ApplicationFiled: April 10, 2019Publication date: May 6, 2021Inventors: Gerben KOOIJMAN, Michael Alex VAN HARTSKAMP, Amir Hussein RMAILE, Carl GLASSE, Marinus Karel Johannes DE JAGER, Philip PRESHAW, John TAYLOR, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT
-
Publication number: 20210109113Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of two or more of the proteins Matrix metalloproteinase-8 (MMP-8), Matrix metalloproteinase-9 (MMP-9), Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient.Type: ApplicationFiled: April 11, 2019Publication date: April 15, 2021Inventors: Gerben KOOIJMAN, Amir Hussein RMAILE, Carl GLASSE, Marinus Karel Johannes DE JAGER, Iain Leslie Campbell CHAPPLE, Melissa Mackay GRANT, Philip PRESHAW, John J. TAYLOR, Michael Alex VAN HARTSKAMP
-
Publication number: 20210063412Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the Free Light Chain ? protein and/or the Free Light Chain ?. Based on the concentration(s) as measured, a value is determined reflecting the concentration or joint concentrations for said protein or proteins. This value is compared with a threshold value reflecting in the same manner the concentration or joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient.Type: ApplicationFiled: January 9, 2019Publication date: March 4, 2021Inventors: GERBEN KOOIJMAN, AMIR HUSSEIN RMAILE, CARL GLASSE, MARINUS KAREL JOHANNES DE JAGER, IAIN LESLIE CAMPBELL CHAPPLE, MELISSA MACKAY GRANT, MICHAEL ALEX VAN HARTSKAMP, PHILIP PRESHAW, JOHN J. TAYLOR
-
Publication number: 20210025903Abstract: Disclosed is an in vitro method for assessing whether a human patient has gingivitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from gingivitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Matrix metal-loproteinase-8 (MMP8), Matrix metalloproteinase-9 (M MP9), Hepatocyte growth factor (HGF), Hemoglobin subunit beta (Hb-beta), and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with gingivitis. The comparison allows assessing whether the testing value is indicative of the presence of gingivitis in said patient.Type: ApplicationFiled: April 10, 2019Publication date: January 28, 2021Inventors: GERBEN KOOIJMAN, AMIR HUSSEIN RMAILE, CARL GLASSE, MARINUS KAREL JOHANNES DE JAGER, IAIN LESLIE CAMPBELL CHAPPLE, MELISSA MACKAY GRANT, PHILIP PRESHAW, JOHN TAYLOR, MICHAEL ALEX VAN HARTSKAMP
-
Publication number: 20200363430Abstract: Disclosed is an in vitro method for assessing whether a human patient is free from periodontal disease, has gingivitis, has mild periodontitis or has advanced periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of the proteins: Alpha-1-acid glycoprotein (A1 AGP) and Pyruvate Kinase (PK), and at least one of the proteins Matrix metalloproteinase-9 (MMP-9) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient is free from periodontal disease, has gingivitis, has mild periodontitis or has advanced periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner joint concentrations associated with gingivitis, mild or advanced periodontitis.Type: ApplicationFiled: January 7, 2019Publication date: November 19, 2020Inventors: GERBEN KOOIJMAN, AMIR HUSSEIN RMAILE, CARL GLASSE, MARINUS KAREL JOHANNES DE JAGER, IAIN LESLIE CAMPBELL CHAPPLE, MELISSA MACKAY GRANT, MICHAEL ALEX VAN HARTSKAMP, PHILIP PRESHAW, JOHN J. TAYLOR
-
Publication number: 20200146132Abstract: The invention provides a light management information system for an outdoor lighting network system, having a plurality of outdoor light units each including at least one sensor type, where each of the light units communicates with at least one other light unit, at least one user input/output device in communication with at one or more of said outdoor light units, a central management system in communication with light units, said central management system sends control commands and/or information to one or more of said outdoor light units, in response to received outdoor light unit status/sensor information from one or more of said outdoor light units or received user information requests from said user input/output device, a resource server in communication with said central management system, wherein the central management system uses the light unit status/sensor information and resources from the resource server to provide information to the user input/output device and/or reconfigure one or more of the lType: ApplicationFiled: January 3, 2020Publication date: May 7, 2020Inventors: HONGXIN CHEN, DAVE ALBERTO TAVARES CAVALCANTI, KIRNA SRINIVAS CHALLAPALI, SANAE CHRAIBI, LIANG JIA, ANDREW ULRICH RUTGERS, YONG YANG, MICHAEL ALEX VAN HARTSKAMP, DZMITRY VIKTOROVICH ALIAKSEYEU, HUI LI, QING LI, FULONG MA, JONATHAN DAVID MASON, BERENT WILLEM MEERBEEK, JOHN B. MILLS, TALMAI BRANDAO DE OLIVEIRA, DANIEL J. PIOTROWSKI, YUAN SHU, NEVEEN SHLAYAN, MARCIN KRZYSZTOF SZCZODRAK, YI QIANG YU, ZHONG HUANG, MARTIN ELIXMANN, QIN ZHAO, XIANNENG PENG, JIANFENG WANG, DAN JIANG
-
Publication number: 20200116738Abstract: Disclosed is an in vitro method for assessing the presence of gingivitis in a human subject. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a saliva sample of the subject the concentrations are measured of the proteins Hepatocyte growth factor (HGF) and Interleukin-1? (IL-1?), and at least one of C reactive protein (CRP) and Haemoglobin. Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with the absence of gingivitis or periodontitis. The comparison allows to assessing whether the testing value is indicative of the presence of gingivitis in said subject. Thereby, typically, a testing value reflecting a joint concentration above the joint concentration reflected by the threshold, is indicative of the presence of gingivitis.Type: ApplicationFiled: May 24, 2018Publication date: April 16, 2020Inventors: GERBEN KOOIJMAN, MICHAEL ALEX VAN HARTSKAMP, MARINUS KAREL JOHANNES DE JAGER, AMIR HUSSEIN RMAILE, PHILIP PRESHAW, JOHN J. TAYLOR
-
Publication number: 20200088741Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Interleukin-1? (IL-1?), Matrix metalloproteinase-9 (MMP-9) and at least one of the proteins: Interleukin-6 (IL-6), and Matrix metalloproteinase-3 (MMP-3). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient.Type: ApplicationFiled: May 23, 2018Publication date: March 19, 2020Inventors: GERBEN KOOIJMAN, SUPRIYO CHATTERJEA, MARINUS KAREL JOHANNES DE JAGER, AMIR HUSSEIN RMAILE, MICHAEL ALEX VAN HARTSKAMP, PHILIP PRESHAW, JOHN TAYLOR